
|Articles|July 21, 2017
GB Sciences Signs Consulting Services Agreement with Worldwide Clinical Trials, Inc.
Advertisement
GB Sciences, Inc. announced it has signed a consulting services agreement with Worldwide Clinical Trials, Inc. to assess the company's intellectual property portfolio and help with pre-IND planning for its cannabis-based formulations. Pre-IND consulting services will be performed by Michael F. Murphy, MD, PhD, chief medical and scientific officer (CMSO) of Worldwide Clinical Trials, Inc.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
2
What the Epilepsy Community Has Taught Us About Trial Feasibility
3
The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026
4
Lab Orchestration Is Not What You Think It Is
5




